Privo Technologies Broadens CLN-004 Clinical Trial at Major Cancer Centers Across the U.S.
Privo Technologies Expands CLN-004 Clinical Trial Across Leading U.S. Cancer Centers
Privo Technologies, Inc., a pioneering biopharmaceutical company, is excited to announce the expansion of its CLN-004 clinical trial across several of the United States' premier cancer centers. With a focus on developing innovative nanotechnology-based therapies for cancer treatment, Privo is moving forward with its Phase 2/3 trial evaluating the safety and efficacy of two of its lead assets—PRV111 and PRV211—aimed at patients suffering from head and neck squamous cell carcinoma (HNSCC).
The trial is now actively recruiting participants at the following distinguished institutions:
- - University of Chicago Medicine (Chicago, IL)
- - City of Hope (Los Angeles, CA)
- - Miami Cancer Institute (Miami, FL)
- - Cleveland Clinic (Cleveland, OH)
Additionally, Privo Technologies is in the process of activating more esteemed cancer centers and will make announcements regarding these collaborations in the near future.
Dr. Manijeh Goldberg, CEO of Privo Technologies, expressed her enthusiasm about collaborating with premier head and neck oncology experts at these prestigious institutions. She stated, “Their participation underscores the potential impact of our novel therapies in transforming the treatment landscape for patients with HNSCC.”
About the CLN-004 Trial
The CLN-004 trial is structured into two distinct arms:
Arm 1: Evaluation of PRV111
This branch of the study focuses on PRV111, a nanoengineered, self-adhesive patch that delivers cisplatin directly to tumor sites. It specifically targets patients diagnosed with carcinoma in situ (CIS) and high-grade dysplasia within the oral cavity. By improving local control of the cancer, PRV111 aims to minimize surgical intervention needs, thus potentially enhancing patient outcomes.
Arm 2: Assessment of PRV211
The second arm investigates PRV211, which functions as an intraoperative chemotherapy system. It is designed to be applied directly into the resected tumor bed during surgical procedures. This targeted approach seeks to eradicate any remaining microscopic disease and mitigate the chances of tumor recurrence for patients categorized under stages T1-T4 HNSCC.
Both PRV111 and PRV211 utilize Privo’s proprietary PRV™ platform, which leverages advanced nanotechnology to optimize the localized delivery of chemotherapy. This innovation aims to maximize the therapeutic effects while significantly reducing systemic toxicity that can arise from conventional cancer treatments.
About Privo Technologies
Privo Technologies is at the forefront of developing groundbreaking therapies addressing the unmet needs in cancer care, particularly for mucosal cancers. By utilizing its PRV™ platform, the company is committed to enhancing patient outcomes through precision-targeted drug delivery systems.
Interested parties are encouraged to visit Privo Technologies’ clinical trial page for more information regarding the CLN-004 trial and participation opportunities.
For media inquiries, please contact:
Stefanie Cantin
Director of Communications
Privo Technologies, Inc.
Email: stefanie.cantin@privotechnologies.com
Phone: (978) 587-2322
Stay tuned for updates as Privo Technologies continues its journey towards groundbreaking cancer therapies, promising a brighter future for those affected by head and neck cancers.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.